Strategic Partnerships OncXerna has established key collaborations with diagnostic and pharmaceutical companies such as Qiagen and Exact Sciences, supporting the development and commercialization of companion diagnostics. These partnerships highlight opportunities for upselling advanced diagnostic solutions and expanding co-development initiatives.

Innovative Platform The company's proprietary RNA expression-based biomarker platform (Xerna™), combined with AI technologies, uniquely positions it to tailor therapies and diagnostic tools, creating potential sales avenues in precision medicine, personalized diagnostics, and targeted oncology treatments.

Focus on Clinical Trials With multiple investigational agents like navicixizumab and bavituximab in early and Phase 2 clinical stages, there is a significant opportunity to support clinical development services, biomarker testing, and trial-related diagnostic solutions for ongoing and future studies.

Market Recognition Being recognized as a top five precision medicine startup underscores its innovative edge and growth potential, making it attractive for investors and strategic partners interested in expanding their portfolio in cutting-edge oncology therapeutics and diagnostics.

Funding and Growth With a $30 million funding round and revenue between $1 million and $10 million, OncXerna is positioned for further development and commercialization efforts, offering sales opportunities in diagnostic tools, clinical services, and early-stage therapeutic solutions tailored to the oncology market.